A study of US male veterans assessed how low PSA needs to go in response to ADT-based regimens to reduce the risk for mCSPC progression and mortality.

Objective: To present management options for gynaecomastia and mastodynia associated with nonsteroidal antiandrogen therapy, supported by relevant data and case studies. Background: Gynaecomastia ...

Finally, it will be important to determine whether the mechanisms of antiandrogen resistance implicated here are relevant to other hormone-dependent diseases such as breast cancer.

Overall survival was analyzed in real-world patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223.

Androgen receptors are present in most advanced prostate cancer specimens, having a critical role in development of this type of cancer. For correct prognosis of patient conditions and treatment ...

Cyproterone acetate (CPA) has in preliminary studies been linked to the development of meningiomas. Possibly, CPA may induce or increase meningioma growth due to antiandrogen and proprogestin ...

Spironolactone and eplerenone both reduce relative mortality in HFrEF by ~30% when added to ACEi. 17 18 Spironolactone is a broad-spectrum mineralocorticoid blocker with side effects relating to its ...